This article discusses the ways we can use PD-L1 status to identify when monotherapy or combination therapy is appropriate in patients with newly diagnosed metastatic non-small-cell lung cancer (mNSCLC).
Optimizing Immunotherapy in NSCLC: Updates from Trials on Agents Targeting PD-L1
Optimizing Immunotherapy in NSCLC: Updates from Trials on Agents Targeting PD-L1
Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and is the leading cause of cancer death in the United States. Estimates for 2019 indicate that NSCLC will account for almost 142,670 deaths despite improvements in targeted treatments for oncogenic alterations, such as mutations in the EGFR (epidermal growth factor receptor) gene and rearrangements of the ALK (anaplastic lymphoma kinase) gene.1 However, the recent emergence of immunotherapy targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors has now revolutionized therapy for patients with NSCLC that do not present with targetable driver mutations. Initially, PD-1 or -L1 inhibitors including nivolumab, pembrolizumab and atezolizumab were approved as second-line therapy for patients with advanced NSCLC who have failed platinum-based chemotherapy.2 In 2016, pembrolizumab was approved as first-line monotherapy treatment in patients with advanced EGFR- and ALK-negative NSCLC who present with ≥50% of PD-L1 expression. It is estimated that only about a third of newly diagnosed patients with advanced NSCLC express such high levels of PD-L1, which is why very few patients are suitable for first-line pembrolizumab monotherapy.3 Thus, there has been an unmet medical need for additional agents and combinations for the treatment and management of patients with advanced NSCLC. To this end, several trials are investigating the safety and efficacy of the PD-1, -L1 targeting agents pembrolizumab and atezolizumab in improving outcomes for patients with advanced NSCLC.2 This article has summarized and evaluated data from phase 3 studies in advanced NSCLC that would be useful to inform treatment decisions for the judicious use of PD-L1 targeted agents.
First-Line Pembrolizumab Monotherapy
Based on results from the KEYNOTE-024 study, frontline pembrolizumab is now the standard of care for selected patients with advanced NSCLC who present with a PD-L1 expression (tumor proportion score – TPS) of ≥50% without an activating EGFR or ALK aberration. Data from this trial showed that pembrolizumab monotherapy was associated with significant improvement in objective response rates (ORR of 45% versus 28%), longer overall survival (OS of 30.2 months), and increased progression-free survival (PFS of 10.3 versus 6.0 months) as compared with platinum-based chemotherapy. Importantly, safety, tolerability, and quality of life analyses also favor use of pembrolizumab monotherapy among the subset of patients with advanced NSCLC and with no evidence of oncogenic driver mutations that express high levels of PD-L1.3
Given that a very small proportion of patients with advanced NSCLC express greater than 50% PD-L1 TPS, the KEYNOTE-042 trial was designed to determine the utility of pembrolizumab monotherapy among patients that express lower levels of PD-L1. This trial included patients with advanced NSCLC that expressed PD-L1 at three thresholds (≥50%, ≥20%, and ≥1%) and compared the safety and efficacy of pembrolizumab alone versus either carboplatin plus paclitaxel (squamous cell histology) or carboplatin plus pemetrexed (non-squamous cell histology). Although the results indicated that the OS was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations (≥50%, 20·0 months versus 12·2 months; ≥20%, 17·7 months versus 13·0 months; and ≥1%, 16·7 months versus 12·1 months), the data are actually nuanced, and as seen in figure 1, the curves representing the two therapy arms cross between 6 to 12 months of treatment.4 Experts therefore caution against using frontline pembrolizumab monotherapy for all patients with advanced NSCLC without sensitizing EGFR or ALK alterations that express low PD-L1 TPS.
Combination Therapy with PD-L1 Targeted Agents
For most fit patients with advanced NSCLC that lack EGFR or ALK mutations, experts now recommend a combination regimen of chemotherapy and pembrolizumab regardless of PD-L1 expression based on results and updates from the KEYNOTE-189 trial.5 In this study, a combination of pembrolizumab plus pemetrexed and a platinum-based drug was associated with significantly longer OS and PFS as compared with chemotherapy alone among patients with advanced, non-squamous NSCLC with any level of PD-L1 level expression.5 Recently, an updated OS analysis confirmed that with an 18.7 months median follow-up, pembrolizumab plus chemotherapy continued to provide longer OS (median 22.0 months versus 10.7 months) (figure 2), which is why it is suggested as first-line therapy among both PD-L1 expressing and PD-L1 non-expressing non-squamous NSCLC.6
For patients with advanced squamous NSCLC, a combination of pembrolizumab, nab-paclitaxel, and carboplatin is suggested based on results from the KEYNOTE-407 trial, which reported an increased median OS from 11.3 to 15.9 months. As seen in figure 3, this improvement was across all PD-L1 subgroups (TPS < 1%, 1–49%, and ≥50%).7
On the other hand, the IMpower-132 study that investigated a different anti-PD-L1 agent, atezolizumab, in combination with carboplatin or cisplatin plus pemetrexed did not show an improved OS and was associated with only an improved PFS in treatment-naïve advanced non-squamous NSCLC in the absence of an activating EGFR or ALK alteration, irrespective of PD-L1 expression.8 Similarly, the IMpower-130 trial determined the efficacy of atezolizumab plus carboplatin and nanoparticle albumin-bound (nab)-paclitaxel and was associated with a trend for OS benefit for patients with advanced, treatment-naïve non-squamous NSCLC.9 Given these results, it is now clear that atezolizumab and pembrolizumab seem to have different efficacies despite both agents targeting the PD-1/PD-L1 axis. However, in the IMpower-150 trial, the quadruplet combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel was associated with a tolerable safety profile and an improved OS as well as PFS along with physical functioning among chemotherapy-naive patients with non-squamous NSCLC.10 Notably, in this trial, the improved OS and PFS were observed regardless of PD-L1 expression and EGFR or ALK genetic alteration status, thereby making this quadruplet regimen applicable to this subset of patients eligible for bevacizumab and also to those ineligible for pemetrexed with borderline renal function.11
NSCLC with Liver Metastases
Liver metastases is common in advanced NSCLC and identifying safe and efficacious regimens for this subset of patients has been urgently warranted. To this end, a subgroup analysis from KEYNOTE-189 demonstrated superior outcomes (improved OS and PFS) upon treatment with the combination of pembrolizumab, pemetrexed, and a platinum-based therapy among advanced NSCLC patients with liver metastases.12 Similarly, an improved median OS was also reported in patients with baseline liver metastases receiving the quadruplet regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel.13 This regimen would require no contraindications to bevacizumab and may provide additional benefit in this subset of patients due to the combination of anti-VEGF and anti-PD-L1 agents rather than PD-1/PD-L1 inhibition alone.
Several trials have evaluated the utility of anti-PD-L1 agents and their combinations in the first-line setting in advanced NSCLC. A review of recently reported data and published studies has led to increased acceptance for testing PD-L1 levels along with driver mutations and for using pembrolizumab monotherapy only among patients expressing higher levels of PD-L1, no driver mutations, and a low volume of disease and low volume of disease-related symptoms. For most other patients with advanced NSCLC, including those with squamous and non-squamous histology, irrespective of PD-L1 status, the triplet combination of a platinum agent/pemetrexed/pembrolizumab or the quadruplet regimen of carboplatin, paclitaxel, atezolizumab and bevacizumab is recommended based on data from the KEYNOTE-189 and Impower 150 trials. The question of sequencing immunotherapy after chemotherapy or vice versa, however, remains currently unanswered. The ongoing INSIGNA [NCT03793179] trial has been designed to address these issues and is widely anticipated.14
1. Key Statistics for Lung Cancer. Available at: https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html. Accessed August 9, 2019.
2. Ackermann CJ, Reck M, Paz-Ares L, Barlesi F, Califano R. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. Lung Cancer. 2019;134:245-253.
3. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2016;375(19):1823-1833.
4. Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2019;393(10183):1819-1830.
5. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2018;378(22):2078-2092.
6. Gadgeel SM, Garassino MC, Esteban E, et al. KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. Journal of Clinical Oncology. 2019;37(15_suppl):9013-9013.
7. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(21):2040-2051.
8. Papadimitrakopoulo V., Cobo M., Bordoni R., et al: IMpower132: PFS and safety results with 1L Atezolizumab + Carbolatin/Cisplatin+Pemetrexed in Stage IV non-squamous NSCLC. J. Thorac. Oncol. 2018; 13: pp. S332-S333.
9. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 2019;20(7):924-937.
10. Socinski MA, Jotte RM, Cappuzzo F, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. Journal of Clinical Oncology. 2018;36(15_suppl):9002-9002.
11. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with <em>EGFR</em> mutations or baseline liver metastases in a randomised, open-label phase 3 trial. The Lancet Respiratory Medicine. 2019;7(5):387-401.
12. Garassino MC, Gadgeel S, Esteban E, et al. Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study. Cancer Research. 2019;79(13 Supplement):CT043-CT043.
13. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine. 2018;378(24):2288-2301.
14. Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT03793179. Accessed August 9, 2019.
- Guest: Mark A. Socinski, MD
Available credits: 0.25
In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Mark A. Socinski, MD
Executive Medical Director, Thoracic Cancer
AdventHealth Medical Group
Dr. Socinski is a speaker for AstraZeneca, Celgene, Genentech, and Guardant Health and has contracted research with AstraZeneca, Genentech, and Spectrum.
- Sean T. Barrett has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
- Brian P. McDonough, MD, FAAFP has nothing to disclose.
- William Mencia, MD, PhD has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Identify patients with mNSCLC who may benefit from immunotherapy monotherapy
- Identify the appropriate forms of combination therapy in patients with mNSCLC with no identified driver mutations
This activity is designed to meet the educational needs of oncologists, pathologists, and pulmonologists.
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Merck.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Millie D. Long, MD, MPHPeer